Leap Therapeutics publishes DeFianCe trial results in journal

Leap Therapeutics Inc. said on Monday its DeFianCe clinical trial results have been published in a peer-reviewed journal, highlighting the efficacy of its investigational therapy.

The DeFianCe trial, which evaluated the company’s lead drug candidate, demonstrated statistically significant outcomes in the primary endpoint, according to Leap Therapeutics. The study’s findings were detailed in a publication in the Journal of Clinical Oncology, a move the company described as a milestone for its research efforts.

Leap Therapeutics, a clinical-stage biotechnology firm, has been developing therapies targeting gastrointestinal cancers. The published data from the DeFianCe trial could support future regulatory discussions and potential partnerships, the company stated. No financial terms or commercial agreements were disclosed in the announcement.

The trial’s results follow prior preclinical and early-phase data that suggested the candidate’s mechanism of action may address unmet medical needs in oncology. Leap Therapeutics did not provide further details on the trial’s design, patient population, or comparative benchmarks.

Shares of Leap Therapeutics were not immediately active in extended trading following the announcement. The company did not respond to requests for additional comment beyond the published statement.